Measuring IGF-1, ER-α and EGFR expression can predict tamoxifen-resistance in ER-positive breast cancer

Anticancer Research

Volumn 31, Issue 1, 2011, Pages 23-32

  Chong, Kelvin Yoon Mann ^a   Subramanian, Ashok ^a   Sharma, Anup ^a   Mokbel, Kefah ^a  

^a ST GEORGE S HOSPITAL   (United Kingdom)

Author keywords

Breast cancer recurrence; EGFR; IGF 1; Insulin like growth factor 1; Oestrogen receptor alpha; Oestrogen resistance; Tamoxifen resistance

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR ALPHA; SOMATOMEDIN C; SOMATOMEDIN C RECEPTOR; TAMOXIFEN;

ADULT; AGED; ARTICLE; BREAST CANCER; CANCER RECURRENCE; GENE EXPRESSION; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MASTECTOMY; METASTASIS; PRIORITY JOURNAL;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS, HORMONAL; BREAST NEOPLASMS; DRUG RESISTANCE, NEOPLASM; ESTROGEN RECEPTOR ALPHA; FEMALE; HUMANS; INSULIN-LIKE GROWTH FACTOR I; MIDDLE AGED; RECEPTOR, EPIDERMAL GROWTH FACTOR; RECEPTOR, IGF TYPE 1; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; TAMOXIFEN;

EID: 79851471665     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (32)

1. Allred DC, Harvey JM, Berardo M and Clark GM: Prognostic and predictive factors in breast cancer by immunohistochemical analysis. Mod Pathol 11: 155-168, 1998. (Pubitemid 28144151)
2. Arpino G, Green SJ, Allred DC, Lew D, Martino S, Osborne CK and Elledge RM: HER-2 amplification, HER-1 expression, and tamoxifen response in estrogen receptor-positive metastatic breast cancer: a southwest oncology group study. Clin Cancer Res 10: 5670-5676, 2004.
3. Brockdorff BL, Heiberg I and Lykkesfeldt AE: Resistance to different antiestrogens is caused by different multi-factorial changes and is associated with reduced expression of IGF receptor Ialpha. Endocr Relat Cancer 10: 579-590, 2003. (Pubitemid 38094892)
4. Ciocca DR and Elledge R: Molecular markers for predicting response to tamoxifen in breast cancer patients. Endocrine 13: 1-10, 2000.
5. Dowsett M, Harper-Wynne C, Boeddinghaus I, Salter J, Hills M, Dixon M, Ebbs S, Gui G, Sacks N and Smith I: HER-2 amplification impedes the antiproliferative effects of hormone therapy in estrogen receptor-positive primary breast cancer. Cancer Res 61: 8452-8458, 2001. (Pubitemid 33131124)
6. Encarnacion CA, Ciocca DR, McGuire WL, Clark GM, Fuqua SA and Osborne CK: Measurement of steroid hormone receptors in breast cancer patients on tamoxifen. Breast Cancer Res Treat 26: 237-246, 1993. (Pubitemid 23304239)
7. Fan M, Yan PS, Hartman-Frey C, Chen L, Paik H, Oyer SL, Salisbury JD, Cheng AS, Li L, Abbosh PH, Huang TH and Nephew KP: Diverse gene expression and DNA methylation profiles correlate with differential adaptation of breast cancer cells to the antiestrogens tamoxifen and fulvestrant. Cancer Res 66: 11954-11966, 2006. (Pubitemid 46094209)
8. Giudice LC, Dsupin BA, Gargosky SE, Rosenfeld RG and Irwin JC: The insulin-like growth factor system in human peritoneal fluid: its effects on endometrial stromal cells and its potential relevance to endometriosis. J Clin Endocrinol Metab 79: 1284-1293, 1994.
9. Gutierrez MC, Detre S, Johnston S, Mohsin SK, Shou J, Allred DC, Schiff R, Osborne CK and Dowsett M: Molecular changes in tamoxifen-resistant breast cancer: relationship between estrogen receptor, HER-2, and p38 mitogen-activated protein kinase. J Clin Oncol 23: 2469-2476, 2005. (Pubitemid 47050837)
10. Heldring N, Pike A, Andersson S, Matthews J, Cheng G, Hartman J, Tujague M, Strom A, Treuter E, Warner M and Gustafsson JA: Estrogen receptors: how do they signal and what are their targets. Physiol Rev 87: 905-931, 2007. (Pubitemid 47084672)
11. Jiang WG, Watkins G, Lane J, Cunnick GH, Douglas-Jones A, Mokbel K and Mansel RE: Prognostic value of rho GTPases and rho guanine nucleotide dissociation inhibitors in human breast cancers. Clin Cancer Res 9: 6432-6440, 2003. (Pubitemid 38031830)
12. Johnston SR, Saccani-Jotti G, Smith IE, Salter J, Newby J, Coppen M, Ebbs SR and Dowsett M: Changes in estrogen receptor, progesterone receptor, and pS2 expression in tamoxifen-resistant human breast cancer. Cancer Res 55: 3331-3338, 1995.
13. Jones HE, Goddard L, Gee JM, Hiscox S, Rubini M, Barrow D, Knowlden JM, Williams S, Wakeling AE and Nicholson RI: Insulin-like growth factor-I receptor signalling and acquired resistance to gefitinib (ZD1839; Iressa) in human breast and prostate cancer cells. Endocr Relat Cancer 11: 793-814, 2004. (Pubitemid 40065552)
14. Konecny G, Pauletti G, Pegram M, Untch M, Dandekar S, Aguilar Z, Wilson C, Rong HM, Bauerfeind I, Felber M, Wang HJ, Beryt M, Seshadri R, Hepp H and Slamon DJ: Quantitative association between HER-2/neu and steroid hormone receptors in hormone receptor-positive primary breast cancer. J Natl Cancer Inst 95: 142-153, 2003. (Pubitemid 36193263)
15. Kudoh M, Susaki Y, Ideyama Y, Nanya T, Mori M and Shikama H: Inhibitory effects of a novel aromatase inhibitor, YM511, on growth of endometrial expiants and insulin-like growth factor-I gene expression in rats with experimental endometriosis. J Steroid Biochem Mol Biol 63: 75-80, 1997. (Pubitemid 28018139)
16. Kurokawa H and Arteaga CL: ErbB (HER) receptors can abrogate antiestrogen action in human breast cancer by multiple signaling mechanisms. Clin Cancer Res 9: 511S-515S, 2003.
17. Law JH, Habibi G, Hu K, Masoudi H, Wang MY, Stratford AL, Park E, Gee JM, Finlay P, Jones HE, Nicholson RI, Carboni J, Gottardis M, Pollak M and Dunn SE: Phosphorylated insulin-like growth factor-i/insulin receptor is present in all breast cancer subtypes and is related to poor survival. Cancer Res 68: 10238-10246, 2008.
18. Migliaccio I, Wu MF, Gutierrez C, Malorni L, Mohsin SK, Allred DC, Hilsenbeck SG, Osborne CK, Weiss H and Lee AV: Nuclear IRS-1 predicts tamoxifen response in patients with early breast cancer. Breast Cancer Res Treat 2009.
19. Nicholson RI, Hutcheson IR, Hiscox SE, Knowlden JM, Giles M, Barrow D and Gee JM: Growth factor signalling and resistance to selective oestrogen receptor modulators and pure anti-oestrogens: the use of anti-growth factor therapies to treat or delay endocrine resistance in breast cancer 4. Endocr Relat Cancer 12(Suppl 1): S29-S36, 2005. (Pubitemid 41395412)
20. Nicholson RI, Hutcheson IR, Knowlden JM, Jones HE, Harper ME, Jordan N, Hiscox SE, Barrow D and Gee JM: Nonendocrine pathways and endocrine resistance: observations with antiestrogens and signal transduction inhibitors in combination 8. Clin Cancer Res 10: 346S-354S, 2004.
21. Osborne CK, Schiff R, Arpino G, Lee AS and Hilsenbeck VG: Endocrine responsiveness: understanding how progesterone receptor can be used to select endocrine therapy. Breast 14: 458-465, 2005.
22. Paik S, Shak S, Tang G, Kim C, Baker J, Cronin M, Baehner FL, Walker MG, Watson D, Park T, Hiller W, Fisher ER, Wickerham DL, Bryant J and Wolmark N: A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. N Engl J Med 351: 2817-2826, 2004.
23. Parisot JP, Hu XF, DeLuise M and Zalcberg JR: Altered expression of the IGF-1 receptor in a tamoxifen-resistant human breast cancer cell line. Br J Cancer 79: 693-700, 1999. (Pubitemid 29082092)
24. Pawlowski V, Revillion F, Hebbar M, Hornez L and Peyrat JP: Prognostic value of the type I growth factor receptors in a large series of human primary breast cancers quantified with a real-time reverse transcription-polymerase chain reaction assay. Clin Cancer Res 6: 4217-4225, 2000.
25. Riggins RB, Schrecengost RS, Guerrero MS and Bouton AH: Pathways to tamoxifen resistance. Cancer Lett 256: 1-24, 2007. (Pubitemid 47333324)
26. Ross JS, Fletcher JA, Bloom KJ, Linette GP, Stec J, Symmans WF, Pusztai L and Hortobagyi GN: Targeted therapy in breast cancer: the HER-2/neu gene and protein. Mol Cell Proteomics 3: 379-398, 2004. (Pubitemid 38702091)
27. Santen RJ: To block estrogen's synthesis or action: that is the question. J Clin Endocrinol Metab 87: 3007-3012, 2002.
28. Schiff R, Massarweh SA, Shou J, Bharwani L, Mohsin SK and Osborne CK: Cross-talk between estrogen receptor and growth factor pathways as a molecular target for overcoming endocrine resistance. Clin Cancer Res 10: 331S-336S, 2004.
29. Sommer A, Hoffmann J, Lichtner RB, Schneider MR and Parczyk K: Studies on the development of resistance to the pure antiestrogen Faslodex in three human breast cancer cell lines. J Steroid Biochem Mol Biol 85: 33-47, 2003. (Pubitemid 36694275)
30. van den Berg HW, Claffie D, Boylan M, McKillen J, Lynch M, and McKibben B: Expression of receptors for epidermal growth factor and insulin-like growth factor I by ZR-75-1 human breast cancer cell variants is inversely related: the effect of steroid hormones on insulin-like growth factor I receptor expression. Br J Cancer 73: 477-481, 1996.
31. van den Berg HW, Lynch M, Martin J, Nelson J, Dickson GR and Crockard AD: Characterisation of a tamoxifen-resistant variant of the ZR-75-1 human breast cancer cell line (ZR-75-9a1) and ability of the resistant phenotype. Br J Cancer 59: 522-526, 1989.
32. Witton CJ, Reeves JR, Going JJ, Cooke TG and Bartlett JM: Expression of the HER1-4 family of receptor tyrosine kinases in breast cancer. J Pathol 200: 290-297, 2003. (Pubitemid 36827302)